Surgical Robotics Technology
FocalTherics has announced that it has entered into an agreement with MellingMedical, a leading SBA-Verified Service-Disabled Veteran-Owned Small Business (SDVOSB), to expand access to Focal One Robotic HIFU (High Intensity Focused Ultrasound) to federal healthcare providers and make its prostate treatment technology available to Veterans and active-duty military personnel throughout the VA and Department of Defense healthcare systems (“Veterans Healthcare System”).
Currently, nearly 500,000 Veterans are receiving prostate cancer treatment or care within the Veterans Healthcare System. Veterans are diagnosed with prostate cancer at two times the rate of the general population and prostate cancer accounts for approximately 30% of new cancer diagnoses among men in the Veterans Healthcare System.
Over the last four years prostate cancer care for Veterans has been an area of increased federal focus, anchored through the 2022 Cleland-Dole Act, which directed the Department of Veterans Affairs to advance comprehensive prostate cancer care for Veterans. Through MellingMedical’s VA Federal Supply Schedule, federal healthcare facilities can now acquire Focal One Robotic HIFU, adding incision-free, radiation-free robotic focal therapy to the treatment options available across the Veterans Healthcare System.
“Bringing Focal One’s revolutionary Robotic HIFU technology to our federal healthcare providers represents a significant advancement in prostate cancer care options for our Veterans,” said Chris Melling, founder and CEO of MellingMedical. “This non-invasive treatment approach offers patients the possibility of maintaining their quality of life while effectively treating their condition, a perfect alignment with our mission to bring innovative healthcare solutions to those who have served our nation.”
“FocalTherics is the leader in robotic focal therapy with a large and growing customer base in the United States,” said Ryan Rhodes, CEO of FocalTherics. “The Veteran population deserves access to the most advanced prostate cancer treatment options. This partnership reinforces our ongoing commitment to expand patient access to Focal One Robotic HIFU without the long-lasting effects of surgery or radiation.”
Source: FocalTherics
